Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/GFH966PMID 16030053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

  2005cited by this paper
• Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.

  2004cited by this paper
• Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

  2004cited by this paper
• On the evolving nature of understanding dialysis-related disorders.

  2003cited by this paper
• Bone metabolism and disease in chronic kidney disease

  2003cited by this paper
• Achievement of proposed NKF-K/DOQI Bone Metabolism and Disease targets Treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism

  2003cited by this paper
• Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

  2003cited by this paper
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

  2003influential reference
• Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: Prevalence and Race

  2003cited by this paper
• Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.

  2003cited by this paper
• The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.

  2003cited by this paper
• Control of parathyroid cell growth by calcimimetics.

  2003cited by this paper
• Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

  2003cited by this paper
• The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

  2003cited by this paper
• The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.

  2002cited by this paper
• Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

  2001cited by this paper
• Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients.

  2001cited by this paper
• Causes and Consequences of Adynamic Bone Disease

  2001cited by this paper
• Consequences of hyperphosphatemia and elevated levels of the calcium-phosphorus product in dialysis patients

  2001cited by this paper
• Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

  2001cited by this paper
• Recent developments in the management of secondary hyperparathyroidism.

  2001cited by this paper
• Current medical management of secondary hyperparathyroidism.

  2000cited by this paper
• Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management.

  2000cited by this paper
• Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone.

  2000cited by this paper
• Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis.

  2000cited by this paper
• High Prevalence of Hyperparathyroidism among Peritoneal Dialysis Patients: A Review of 176 Patients

  2000cited by this paper
• Pathogenesis of secondary hyperparathyroidism.

  1999cited by this paper
• Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences.

  1999cited by this paper
• Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism.

  1998cited by this paper
• Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

  1998cited by this paper
• Hyperparathyroidism in the hemodialysis population: a survey of 612 patients.

  1997cited by this paper
• Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells.

  1997cited by this paper
• Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity.

  1995cited by this paper
• Pathogenesis of secondary hyperparathyroidism.

  1994cited by this paper
• Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.

  1989cited by this paper

• Evocalcet improved the PTH-calcium setpoint and suppressed parathyroid proliferation in mice model of primary hyperparathyroidism.

  2026cites this paper
• The impact of cinacalcet on the serum phosphorus, calcium and PTH levels in dialysis patients; a systematic review and meta-analysis

  2024cites this paper
• An unusual cause of pulmonary infiltrates mimicking pulmonary edema: metastatic calcifications

  2022cites this paper
• How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?

  2022cites this paper
• Old and New Drugs for the Management of Bone Disorders in CKD

  2021cites this paper
• The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism

  2021cites this paper
• Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture

  2020cites this paper
• Drugs acting on the calcium receptor

  2020cites this paper
• Les inhibiteurs de la voie Wnt dans un modèle animal d'insuffisance rénale chronique avec calcification vasculaire

  2020cites this paper
• Mineral Bone Disorders in Chronic Kidney Disease

  2019cites this paper
• Effects of Long-Term Cinacalcet Administration on Parathyroid Gland in Hemodialysis Patients with Secondary Hyperparathyroidism

  2019cites this paper
• Relationship between parathyroid oxyphil cell proportion and clinical characteristics of patients with chronic kidney disease

  2019cites this paper
• Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

  2018cites this paper
• Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review

  2017cites this paper
• A strategy change in the treatment of end-stage renal disease related hyperparathyroidism after the introduction of calcimimetics: a retrospective observational study

  2016cites this paper
• Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.

  2016cites this paper
• Post-transcriptional Regulation of Parathyroid Hormone Gene Expression in Health and Disease

  2016cites this paper
• Post-transcriptional Mechanisms in Endocrine Regulation

  2016cites this paper
• A rare manifestation of renal osteodystrophy in a non-compliant child on hemodialysis: Answers

  2016cites this paper
• The Calcium-Sensing Receptor and the Parathyroid: Past, Present, Future

  2016cites this paper
• Hyperphosphatemia Management in Patients with Chronic Kidney Disease

  2015cites this paper
• Surgical management of secondary hyperparathyroidism in chronic kidney disease—a consensus report of the European Society of Endocrine Surgeons

  2015cites this paper
• Role of surgery in the treatment of renal secondary hyperparathyroidism

  2015cites this paper
• Advances in pharmacotherapy for secondary hyperparathyroidism

  2015cites this paper
• Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study

  2015cites this paper
• Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

  2014cites this paper
• Parathyroid gland function in dialysis patients

  2014cites this paper
• Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism

  2014cites this paper
• Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.

  2014cites this paper
• Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.

  2013cites this paper
• Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.

  2013cites this paper
• Multiple endokrine Neoplasien

  2013cites this paper
• Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet.

  2013cites this paper
• Rapid Decrease of Intact Parathyroid Hormone Could Be a Predictor of Better Response to Cinacalcet in Hemodialysis Patients

  2013cites this paper
• The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.

  2013cites this paper
• A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet

  2013cites this paper
• Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis.

  2013cites this paper
• Vitamin D, Calcimimetic Agents, and Phosphate Binders

  2012cites this paper
• Tertiary Hyperparathyroidism Pathogenesis, Clinical Features, and Medical Management

  2012cites this paper
• Vitamin D Receptor Activator Selectivity in the Treatment of Secondary Hyperparathyroidism

  2012cites this paper
• Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study.

  2012cites this paper
• THE SIGNIFICANCE OF CINACALCET IN CORRECTION OF PHOSPHORUS-CALCIUM DISBALANCE IN PATENTS WITH CHRONIC KIDNEY DISEASE

  2012cites this paper
• Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy

  2012influential citation
• A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries

  2012cites this paper
• An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects

  2012cites this paper
• Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States

  2012cites this paper
• Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism

  2012cites this paper
• Molecular Mechanisms of Parathyroid Hormone Synthesis

  2012cites this paper
• Effect of cinacalcet on bone mineral density of the radius in hemodialysis patients with secondary hyperparathyroidism.

  2011cites this paper
• CHAPTER 28 – Hormones and Disorders of Mineral Metabolism

  2011cites this paper
• Structure-function studies of M4 muscarinic acetylcholine receptor allosteric modulation

  2011cites this paper
• Molecular Understanding and Assessment of Hypoparathyroidism

  2011cites this paper
• Parathyroidectomia: treatment of secondary hyperparathyroidism. Causes and prophylaxis of disease relapse

  2011cites this paper
• Therapeutic Drug Development for Kidney Diseases

  2011cites this paper
• Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.

  2011cites this paper
• Reduction of whole PTH/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism

  2011cites this paper
• Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

  2011cites this paper
• Lipid peroxidation and parathyroid hormone influence the cytosolic calcium levels of erythrocytes in peritoneal dialysis patients.

  2011cites this paper
• Novel calcium sensing receptor ligands: a patent survey

  2011cites this paper
• Clinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case series

  2011cites this paper
• Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride

  2011cites this paper
• Cinacalcet

  2011cites this paper
• Análisis de coste-utilidad de cinacalcet en el hiperparatiroidismo secundario en España

  2011cites this paper
• New insights into the role of calcium-sensing receptor activation.

  2011cites this paper
• Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?

  2010influential citation
• Long-term control of parathyroid hormone and calcium-phosphate metabolism after parathyroidectomy in children with chronic kidney disease.

  2010cites this paper
• Low -turnover (adynamic) bone disease in CKD patients

  2010cites this paper
• Brown tumors in patients with chronic renal failure and secondary hyperparathyroidism: report of 12 cases.

  2010cites this paper
• Residue 826 in the Calcium-Sensing Receptor Is Implicated in the Response to Calcium and to R-568 Calcimimetic Compound

  2010cites this paper
• Decreases in Parathyroid Gland Volume after Cinacalcet Treatment in Hemodialysis Patients with Secondary Hyperparathyroidism

  2010cites this paper
• Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients.

  2010cites this paper
• Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism

  2010cites this paper
• Hyperparathyroidism.

  2009cites this paper
• Survey of adverse events during treatment with cinacalcet hydrochloride in dialysis patients with secondary hyperparathyroidism

  2009cites this paper
• Cinacalcet in Hyperfunctioning Parathyroid Diseases

  2009cites this paper
• Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.

  2009cites this paper
• Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder.

  2009cites this paper
• Chronic Kidney Disease-Related Mineral and Bone Disorders

  2009cites this paper
• Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.

  2009cites this paper
• Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.

  2009cites this paper
• Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.

  2009cites this paper
• Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder

  2009cites this paper
• Review article: Risks of coronary artery calcification in chronic kidney disease: Do the same rules apply?

  2009cites this paper
• Uso dei calciomimetici nell’iperaparatiroidismo secondario

  2009cites this paper
• I calciomimetici nell'iperparatiroidismo primitivo e secondario

  2009cites this paper
• New strategies for the treatment of hyperparathyroidism incorporating calcimimetics

  2008cites this paper
• Secondary Hyperparathyroidism and Chronic Kidney Disease

  2008cites this paper
• Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism

  2008cites this paper
• A New Paradigm for the Treatment of Secondary Hyperparathyroidism

  2008cites this paper
• Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease

  2008cites this paper
• Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease

  2008cites this paper
• Recent updates on the calcium-sensing receptor as a drug target.

  2008cites this paper
• Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs

  2008cites this paper
• Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.

  2008cites this paper
• Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy

  2008cites this paper
• Impact of Cinacalcet Hydrochloride on Bone Histology in Patients with Secondary Hyperparathyroidism

  2008cites this paper
• Cinacalcet is efficacious in pediatric dialysis patients

  2008cites this paper
• Calcimimetics in CKD—results from recent clinical studies

  2008cites this paper
• The role of bone biopsy in patients with chronic renal failure.

  2008cites this paper
• Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

  2008cites this paper